Bujarski Stephen, Parulekar Amit D, Hanania Nicola A
a Section of Pulmonary, Critical Care and Sleep Medicine , Baylor College of Medicine , Houston , Texas.
Expert Opin Biol Ther. 2016;16(6):847-852. doi: 10.1080/14712598.2016.1182152. Epub 2016 May 10.
Severe asthma continues to be a major clinical problem despite the availability of effective asthma medications such as inhaled corticosteroids. Several targeted biologic therapies are emerging to treat patients with severe asthma. Areas Covered: This review provides an update of information on lebrikizumab, a novel monoclonal antibody that targets IL-13 and is currently in advanced stages of development. It describes the role of IL-13, a key effector cytokine in Type 2 (T2) airway inflammation in asthma and discusses the results of recent phase 2 trials investigating lebrikizumab's efficacy and safety in patients with severe asthma. Furthermore, it provides insight into the current ongoing trials with lebrikizumab and outlines future research needs. Expert Opinion: Several emerging therapeutic targets have been identified for patients with severe asthma. By specifically targeting IL-13, lebrikizumab has the potential to block several downstream signals that play a role in disease progression including airway inflammation, mucous hypersecretion and airway remodeling. The effects of lebrikizumab have been more marked in individuals with high serum periostin levels which reflect underlying IL-13 activity and T2 airway inflammation. Ongoing trials with lebrikizumab aim to further examine its long-term safety and efficacy in a larger population and explore its effects on airway inflammation and function.
尽管有吸入性糖皮质激素等有效的哮喘药物，但重度哮喘仍然是一个主要的临床问题。几种靶向生物疗法正在兴起，用于治疗重度哮喘患者。涵盖领域：本综述提供了关于lebrikizumab的最新信息，lebrikizumab是一种新型单克隆抗体，靶向白细胞介素-13（IL-13），目前正处于研发后期。它描述了IL-13在哮喘2型（T2）气道炎症中的关键效应细胞因子作用，并讨论了近期调查lebrikizumab对重度哮喘患者疗效和安全性的2期试验结果。此外，它深入探讨了目前正在进行的lebrikizumab试验，并概述了未来的研究需求。专家意见：已为重度哮喘患者确定了几个新出现的治疗靶点。通过特异性靶向IL-13，lebrikizumab有可能阻断在疾病进展中起作用的几个下游信号，包括气道炎症、黏液分泌过多和气道重塑。lebrikizumab在血清骨膜蛋白水平高的个体中效果更为显著，血清骨膜蛋白水平反映了潜在的IL-13活性和T2气道炎症。正在进行的lebrikizumab试验旨在进一步研究其在更大人群中的长期安全性和疗效，并探索其对气道炎症和功能的影响。
